AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Warnings about the potential for suicidality and worsening of depression during treatment with antidepressants for major depressive disorder have begun to appear in the label of antidepressant drugs, in response to a request made by the Food and Drug Administration in March.
At press time, those changes had been made in the labels for venlafaxine (Effexor and Effexor XR), nefazodone (Serzone), bupropion (Wellbutrin, Zyban), citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), and paroxetine (Paxil).
The warnings, which apply to both adult and pediatric patients with major depressive disorder, recommend that patients be observed closely for clinical worsening and the emergence of suicidal ideation and behavior, particularly when they begin treatment and when the dose is changed.
The warnings also advise families and caregivers of such patients to be alert to ...